In the rapidly evolving landscape of the human microbiome, Clostridium scindens has emerged as a keystone species with profound implications for metabolic health and pathogen resistance. As a premier Contract Research Organization (CRO) specializing in preclinical Live Biotherapeutic Product (LBP) development, Creative Biolabs provides a comprehensive suite of research services and high-quality microbial products centered on C. scindens. From elucidating bile acid transformation pathways to validating therapeutic efficacy in gnotobiotic models, our platform is designed to accelerate your microbiome-based drug discovery from the bench to the clinic.
Overview: The Keystone Role of Clostridium scindens
Clostridium scindens is a commensal, gram-positive, anaerobic bacterium belonging to the Clostridium cluster XIVa. While it typically exists in low abundance within the human gut, its functional impact is disproportionately large. It is one of the few known species capable of performing 7α-dehydroxylation, a critical biochemical process that converts primary bile acids (produced by the liver) into secondary bile acids, such as Deoxycholic Acid (DCA) and Lithocholic Acid (LCA).
These secondary bile acids are not merely metabolic byproducts; they serve as potent signaling molecules that regulate host metabolism, immune responses, and the integrity of the intestinal barrier. Research has positioned C. scindens as a "bioreactor" within the gut, making it a primary candidate for Live Biotherapeutic development.
Our Preclinical Research Services
We provide a comprehensive suite of CRO services specifically optimized for the unique growth and metabolic requirements of Clostridium scindens.
-
CDI Challenge Models: Testing your LBP candidate in antibiotic-treated or gnotobiotic mouse models infected with C. difficile.
-
DSS-Induced Colitis Models: Assessing mucosal healing and inflammatory markers (cytokine profiling, histology).
-
Gnotobiotic (Germ-Free) Services: Mono-colonization or defined-consortia studies to isolate the specific effects of C. scindens.
Bioanalytical Services
-
Targeted Metabolomics: High-sensitivity LC-MS/MS for the quantification of 30+ bile acid species in feces, serum, and bile.
-
Transcriptomics: Evaluating host gene expression (e.g., TGR5, FXR, FGF15) in response to C. scindens colonization.
Specialized Products for Research
To support your internal R&D, we offer a range of high-quality materials:
Standardized Strains: Quality-controlled C. scindens
Genomic DNA
|
Product Name
|
Catalog No.
|
Target
|
Product Overview
|
Datasheet
|
Price
|
|
Clostridium scindens Genomic DNA
|
LBGF-0925-GF1174
|
Clostridium DNA
|
This product contains high-quality, intact genomic DNA isolated from Clostridium scindens Genomic DNA. It is a purified and ready-to-use DNA sample, ideal for a wide range of molecular biology applications, including PCR, qPCR, and Next-Generation Sequencing.
|
Datasheet
|
$720.00
|
Research Applications: Targeting Disease Through Metabolic Modulation
The therapeutic potential of C. scindens spans several critical disease areas, primarily driven by its unique enzymatic capabilities.
1. Clostridioides difficile Infection (CDI)
The most well-established application of C. scindens is in providing colonization resistance against C. difficile. By producing secondary bile acids (DCA/LCA), C. scindens inhibits the germination and vegetative growth of C. difficile spores. Preclinical studies utilize C. scindens to restore microbial "colonization resistance" in antibiotic-depleted microbiomes, offering a targeted alternative to fecal microbiota transplants (FMT).
Emerging research (notably recent 2025 findings) indicates that C. scindens facilitates intestinal healing. Secondary bile acids produced by the strain activate the TGR5 receptor, which stimulates the proliferation of intestinal stem cells and regenerates the gut lining. Reducing chronic inflammation and promoting mucosal recovery in Ulcerative Colitis models.
Beyond bile acids, C. scindens possesses steroid-17,20-desmolase activity, allowing it to convert glucocorticoids into androgens. This makes it a focal point for research into:
-
Hormonal Imbalances: Understanding the gut-microbiome-endocrine axis.
-
Liver Disease: Managing cholestasis and non-alcoholic fatty liver disease (NAFLD) by modulating the total bile acid pool.
4. Pathogen Protection (Non-CDI)
Recent in vitro co-culture studies have demonstrated that C. scindens can protect the colonic epithelium against other pathogens like Staphylococcus aureus by repressing enterotoxin production and maintaining epithelial barrier function.
Why Choose Us?
Developing C. scindens therapeutics requires specialized expertise in anaerobic microbiology and bile acid metabolism. We make it accessible.
Anaerobic Expertise
Our facility is equipped with state-of-the-art anaerobic chambers and bioreactors, ensuring the viability of the most sensitive obligate anaerobes.
Metabolic Specialization
We don't just count bacteria; we measure their function. Our focus on bile acid metabolism sets us apart from generalist microbiome CROs.
Regulatory Readiness
Our preclinical data packages are designed to support IND (Investigational New Drug) filings for Live Biotherapeutics.
Customization
We tailor every study design to your specific therapeutic hypothesis and target indication.
The therapeutic potential of Clostridium scindens represents a paradigm shift in how we treat intestinal and metabolic diseases. By harnessing the body's own chemical factory, we can restore balance to the gut ecosystem and offer new hope to patients with refractory conditions.
At Creative Biolabs, we are more than a service provider; we are your intellectual partner in microbiome discovery. Whether you are a startup exploring a novel LBP or a pharmaceutical leader validating a new drug target, our expertise in C. scindens and bile acid biology will ensure your research is robust, reproducible, and ready for the clinic.
Would you like me to refine the technical specifications for the bioanalytical section or perhaps generate a sample study design for a C. difficile challenge model? Ready to accelerate your Live Biotherapeutic program? Contact us today.
Frequently Asked Questions (FAQs)
Is C. scindens safe for use in human therapeutics?
As a natural commensal of the human gut, C. scindens has a strong safety profile. However, its potential to produce pro-carcinogenic secondary bile acids at high concentrations means that dosing and strain selection are critical components of preclinical safety assessment.
Can C. scindens perform 7α-dehydroxylation in isolation?
In vivo, C. scindens often requires a "partner" species that possesses Bile Salt Hydrolase (BSH) activity to first deconjugate bile salts. We offer co-colonization models to study these interspecific synergies.
What is the lead time for a gnotobiotic mouse study?
Typically, gnotobiotic studies require 12–16 weeks, including animal acclimation and colonization verification.
